glp 1 cardiovascular risk reduction disease continuum-GLP-1 action. Adapted from [46] Interrupting or stopping GLP-1s may

Targeted Delivery: Can be administered to specific areas for focused repair and rejuvenation

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit

So injecting near the injury doesn't give you any extra benefit, and going intramuscular instead of subcutaneous just adds discomfort for no real upside

GLP-1R activation inhibits NF-kB through a series of complicated actions inside the cell, but ultimately for our purposes this leads to the downregulation of multiple inflammatory cytokines, including but not limited to Tumor Necrosis Factor Alpha, (TNF-a) Interleukin 6 and 1-beta (IL6 and IL-1b) and multiple others

For administering your research doses, you'll need a standard U-100 insulin syringe, which is marked in units for precise measurement

Now, many of these inducers will only reduce ethinyl estradiol/progesterone by 10%20%, but the risk is nontrivial and the science inexact, so double protection is a wise strategy here